Elan Corp. (NYSE: ELN) swung to a profit for the fourth quarter but the company announced a restructuring of its Tysabri agreement granting full rights of the drug to Biogen (Nasdaq: BIIB). Shares of Elan fell 97 cents to $9.49 while Biogen stock leaped $4.51 to $161.87.